Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer

Basit Öğe Kaydı
dc.authoridIlikci Sagkan, Rahsan/0000-0003-3844-6158
dc.contributor.authorIlikci Sagkan, Rahsan
dc.contributor.authorAkin-Bali, Dilara Fatma
dc.date.accessioned2024-11-07T13:32:04Z
dc.date.available2024-11-07T13:32:04Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractRecent days have seen growing evidence of cancer's susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of the effect of genomic differences on the virus' entrance genes in lung cancer. Genetic confirmation of the hypotheses regarding gene expression and mutation pattern of target genes, including angiotensin-converting enzyme-2 (ACE2), transmembrane serine protease 2 (TMPRSS2), basigin (CD147/BSG) and paired basic amino acid cleaving enzyme (FURIN/PCSK3), as well as correlation analysis, was done in relation to lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) using in silico analysis. Not only were gene expression and mutation patterns detected, but also there were correlation and survival analysis between ACE2 and other target genes expression levels. The total genetic anomaly carrying rate of target genes, including ACE2, TMPRSS2, CD147/BSG, and FURIN/PCSK3, was determined as 8.1% and 21 mutations were detected, with 7 of these mutations having pathogenic features. p.H34N on the RBD binding residues for SARS-CoV-2 was determined in our LUAD patient group. According to gene expression analysis results, though the TMPRSS2 level was statistically significantly decreased in the LUSC patient group compared to healthy control, the ACE2 level was determined to be high in LUAD and LUSC groups. There were no meaningful differences in the expression of CD147 and FURIN genes. The challenge for today is building the assessment of genomic susceptibility to COVID-19 in lung cancer, requiring detailed experimental laboratory studies, in addition to in silico analyses, as a way of assessing the mechanism of novel virus invasion that can be used in the development of effective SARS-CoV-2 therapy.
dc.identifier.doi10.1002/jmv.26107
dc.identifier.endpage2647
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.issue11
dc.identifier.pmid32492203
dc.identifier.scopus2-s2.0-85087154968
dc.identifier.scopusqualityQ1
dc.identifier.startpage2637
dc.identifier.urihttps://doi.org/10.1002/jmv.26107
dc.identifier.urihttps://hdl.handle.net/11480/15203
dc.identifier.volume92
dc.identifier.wosWOS:000541087600001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Medical Virology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectACE2
dc.subjectCD147
dc.subjectCovid-19
dc.subjectFURIN
dc.subjectlung cancer
dc.subjectsevere acute respiratory syndrome coronavirus 2
dc.subjectTMPRSS2
dc.titleStructural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu